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Detection of DNA is an important determinant of host-defense but also a driver of
autoinflammatory and autoimmune diseases. Failure to degrade self-DNA in DNAseII
or III(TREX1)-deficient mice results in activation of the cGAS-STING pathway. Deficiency
of cGAS or STING in these models ameliorates disease manifestations. However, the
contribution of the cGAS-STING pathway, relative to endosomal TLRs, in systemic lupus
erythematosus (SLE) is controversial. In fact, STING deficiency failed to rescue, and
actually exacerbated, disease manifestations in Fas-deficient SLE-prone mice. We have
now extended these observations to a chronic model of SLE induced by the i.p. injection
of TMPD (pristane). We found that both cGAS- and STING-deficiency not only failed to
rescue mice from TMPD-induced SLE, but resulted in increased autoantibody production
and higher proteinuria levels compared to cGAS STING sufficient mice. Further, we
generated cGASKOFaslpr mice on a pure MRL/Faslpr background using Crispr/Cas9
and found slightly exacerbated, and not attenuated, disease. We hypothesized that
the cGAS-STING pathway constrains TLR activation, and thereby limits autoimmune
manifestations in these two models. Consistent with this premise, mice lacking cGAS
and Unc93B1 or STING and Unc93B1 developed minimal systemic autoimmunity as
compared to cGAS or STING single knock out animals. Nevertheless, TMPD-driven
lupus in B6 mice was abrogated upon AAV-delivery of DNAse I, implicating a DNA
trigger. Overall, this study demonstrated that the cGAS-STING pathway does not
promote systemic autoimmunity in murine models of SLE. These data have important
implications for cGAS-STING-directed therapies being developed for the treatment of
systemic autoimmunity.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a number of
clinical manifestations including systemic inflammation, development of pathogenic antibodies,
deposition of immune complexes and finally end organ damage (1). Genetic predisposition,
environmental factors as well as both innate and adaptive arms of the immune system play an
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important role in initiation and amplification of this disease.
Innate immune sensors present in endosomal compartments
and in the cytosol, such as TLR9 and cGAS, respectively,
can detect both microbial and host nucleic acids. It’s been
established in numerous murine models, that the endosomal
TLRs, TLR7, and TLR9, play a critical role in SLE and related
systemic autoimmune diseases (2, 3), while the role of STING in
SLE is more controversial. Importantly, loss of function (LOF)
mutations in the extracellular DNAse, DNAse1L3, originally
identified in SLE patients (4–6), results in the accrual of
DNA/RNA-associated microparticles in the blood (7–9). In mice,
genetic deletion of DNAse1L3 promotes an SLE-like disease
through a mechanism that is dependent on TLR7 and TLR9 and
not STING (7, 9).
By contrast, LOF mutations of cytosolic DNAses such as
DNAse II or DNAse III (Trex1) in patient populations are
associated with systemic monogenic autoinflammatory diseases
(10, 11). Genetic deletion of these cytosolic nucleases in mice,
leads to embryonic lethality (DNAse II) (12) or myocarditis
(TrexI) (13) through mechanisms dependent on the cGAS-
STING pathway (14, 15). These data suggest that SLE is
driven by extracellular DNA that is delivered to endosomal
TLRs through receptors such as the BCR, LL37, or FcγRs
while monogenic autoinflammatory diseases are driven by the
aberrant accumulation of DNA in the cytosol that is detected
by the cGAS/STING pathway. Autoantibody production has
been detected in both Trex1 and DNAse II/IFNAR double
deficient mice however, autoantibodies in DNAse II/IFNAR
double defiicent mice have been shown to be Unc93B1 dependent
(16). In addition, autoimmunity in DNAseIL3-deficient mice is
dependent on endosomal MyD88 and endosomal TLRs (17).
Nevertheless, the cGAS/STING pathway has been postulated
as a driver of lupus pathogenesis, although direct evidence for this
is still limited. STINGwas recenlty implicated in the autoimmune
phenotypes that develop in FcγR2-/- mice on a 129 background.
However, since these mice were intercrossed with B6 STINGgt
mice, the potential contribution of 129-associated risk alleles
linked to the STING locus need to be considered (18). cGAMP,
the cyclic dinucleotide generated by cGAS that activates STING,
has been shown to be modestly elevated in the serum of a limited
number of SLE patients (19). Most recently, UVB exposure
which can drive lupus flares leads to an elevated type I IFN-
I gene signature in the skin of mice which is dependent on
the cGAS pathway and enhanced when cGAMP hydrolysis is
blocked (20). Elevated STING activity has further been associated
with increased expression of type I IFNs and ISGs (21, 22) and
the degradation of damaged mitochondrial DNA by autophagy
in patient populations (23). Moreover, while point mutations
in human TREX1, that eliminate catalytic activity, cause the
autoinflammatory disease Aicardi-Goutieres, point mutations
in the N-terminus of TREX1, that retain DNAse activity, are
associated with SLE and other unrelated conditions (24). The N-
terminal mutations disrupt STING localization, and also disrupt
the activity of the ER-resident enzyme oligosaccharyltransferase
(OST) (25). In the absence of OST activity, immunogenic glycans
accumulate in the ER and are the likely explanation for the
association between the N-terminal mutations and SLE (24).
Murine models of C-terminal and N-terminal TREX1
mutations also develop distinct phenotypes. Patients
heterozygous for a mutation that abrogates TREX1 catalytic
activity, D18N, develop a skin disease that resembles
familial chilblain lupus, while mice homozygous for this
mutation develop myocarditis, multi-organ inflammation and
autoantibody production, similar to TREX1−/− mice (26). By
contrast, mice homozygous for C-terminal frameshift mutation,
D272fs, previously associated with SLE (27), exhibit no clinical
manifestations of disease but do develop high autoantibody
titers primarily directed against non-nuclear antigens, and thus
distinct from the autoantibody specificities associated with SLE
(28). Therefore, the association between TREX1 mutations and
murine lupus is weak.
We previously generated STING/Fas double deficient
autoimmune prone mice and found that STING deficient mice
developed more severe, not less severe, disease compared to
Fas-deficient autoimmune prone controls (29). Mechanistically,
we showed that STING-deficient macrophages expressed
decreased levels of negative regulators of immune activation
and therefore were hyper-responsive to TLR ligands (29).
Together, our data indicated that the STING pathway does not
promote, but rather constrains, TLR-driven lupus-like diseases.
However, our prior work used STING-deficient autoimmune
mice that were generated by intercrossing STING-deficient
B6/129 and MRL/Faslpr mice; a limitation to these F2 studies
was the potential contribution of risk alleles derived from the
B6/129 background, that could be linked to the STING locus
in the STING-deficient mice. Moreover, a critical question that
remained unexplored was whether the regulatory effects of
STING were dependent on the upstream DNA sensor cGAS.
To address these issues, we have now further defined the
role of STING and cGAS by directly targeting MRL/lpr mice
using CRISPR/Cas9 genome editing. There has also been some
concerns in the literature regarding the relevance of the MRL/lpr
model to human disease. To address this concern, we have also
expanded our analysis to the chronic model of TMPD-induced
SLE in both cGAS- and STING-deficient B6 mice. We found
that neither cGAS- nor STING- deficiency protected MRL/lpr
mice. We also found that neither cGAS- nor STING-deficiency
prevented TMPD-induced lupus. These studies further confirm
our original observations and demonstrate that STING does
not promote murine SLE in either genetically programmed or
inducible models of SLE.
One caveat to the TMPD model is that it is thought to
be driven predominantly by the RNA-sensing TLR, TLR7 (30,
31) bringing into question the actual role of DNA sensors in
these mice. To evaluate the potential role of DNA sensors in
the TMPD model, we overexpressed DNAseI using an AAV9
gene therapy approach by injecting an AAV9-DNAse I vector
i.p., prior to the TMPD inoculation. The DNAseI expressing
mice developed much less severe clinical manifestations than
mice injected with the vector control. Thus, DNA contributes
to systemic inflammation in TMPD injected mice, along with
TLR7 ligands. Overall, our study shows that the cGAS-STING
pathway is not a driver of disease in TLR-dependent models
of SLE, but instead constrains disease activity, presumably by
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limiting TLR activation. Nonetheless, DNA sensing still plays
an important role in mediating autoimmune pathologies and




Wild-type C57BL/6 mice were purchased from the Jackson
Laboratory. STINGKO mice, fully backcrossed to the C57BL/6
background, were kindly provided by Dr. Daniel Stetson
University of Washington, Seattle, WA (32). cGASKO mice
on a B6 background were generated using cryopreserved
embryos obtained from the European Conditional Mouse
Mutagenesis Program (EUCOMM). cGASKO MRL/MpJ-
Faslpr mice were generated via CRISPR/Cas9 genome
editing at Merck & Co., Inc., Kenilworth, NJ using two
gRNA sequences “AGGACCAGAACACCTTGTAG” and
“TGACCGCACGACTTACCCTG” targeting exon 2. The deletion
of exon 2, resulting in 581bp deletion, was confirmed using
common forward primer 5′CCTAGCCTTGGCTATGTGGT3′
and reverse primer 5′AACAGTTCTAAATAACCGCTTTCG3′
for WT and 5′GAGCTGTAGATGCCCAAGTG3′ reverse primer
for cGASKO. Unc93B1KO mice were provided by Eicke Latz,
University of Massachusetts Medical School, Worcester, MA
(33). All mice were bred and maintained at the Department of
Animal Medicine of the University of Massachusetts Medical
School in accordance with the regulations of the American
Association for the Accreditation of Laboratory Animal Care,
and all protocols were approved by the Institutional Animal Care
and Use Committee.
TMPD and AAV Injection
12–16-week-old mice received a single intraperitoneal injection
of 500 ul of 2,6,10,14-Tetramethylpentadecane (TMPD, Sigma)
and were analyzed 5–6 months after TMPD injection (34).
In some experiments, C57BL/6 mice were injected with either
AAV9-GFP or AAV9-DNAse1 10 weeks prior to TMPD
injections (35). Each mouse received 1011 virus particles in
200 uL PBS delivered by intraperitoneal injection and AAV
expression was measured by qPCR.
Flow Cytometry
Peritoneal exudate was collected in Hanks’ Balanced Salt Solution
(HBSS) media. Single cell suspensions obtained from the
peritoneal cavity were stained with the following antibodies: anti-
CD11b PercpCy5.5, anti-F4/80 PECy7, anti-Ly-6C APC, anti-
Tim4 PE and anti-Ly-6G FITC. Flow cytometric analysis was
carried out using a BD LSRII with Diva software (BD) and
FlowJo Software (Tree Star). Live and single cells were gated to
identify CD11b+ cells which were then gated to identify Ly6Chi
monocytes and Ly6Ghi granulocytes. Macrophages post TMPD
injections were identified as live and single cells that were Ly6C−
Ly6G− Tim4− CD11b+ and F4/80hi expressing cells. Splenocytes
were stained with anti-CD11c pacific blue, SiglecH PE, anti-Bst2
APC, anti-CD3 PerCPCy5.5, anti-B220 Pacific blue, anti-CD4
PECy7 and anti-CD8 PE.
Generation of Bone Marrow Derived
Macrophages
Bone marrow extracts were differentiated in vitro into bone
marrow derived macrophages (BMDMs) in the presence of
L929 supernatants for 7 days. The rested BMDMs were then
transfected with ISD (interferon stimulatory DNA) (5µM)
overnight using Lipofectamine 2000 from Invitrogen.
Measurement of Serum Autoantibodies
HEp-2 human tissue culture substrate slides (MBL Code
# ANK-120) were incubated with serum samples and bound
antibodies were detected with DyLight 488-coupled detecting
reagents as described in Christensen et al. (2). Anti–nucleosome
concentrations were measured by ELISA with absorbance at
405/630 nm and compared with PL2-3 (in-house) as previously
described (2). Autoantibodies reactive with dsDNA were
measured by ELISA. Calf thymus DNA (Sigma) treated with
S1 nuclease (ThermoFisher) was incubated for 1 h at room
temperature on to poly-L-lysine treated ELISA plates. 1:50
diluted mouse sera was used and goat anti-mouse IgG H&L
(HRP) (ab205719) was used as a secondary antibody. Anti-ds
DNA antibody (ab27156) was used as standard.
Proteinuria and Cytokine Measurement
An anti-mouse albumin ELISA kit was used to measure urine
protein as per manufacturer’s protocol (Bethyl Laboratories).
Serum cytokine levels were determined using ELISA kits
as per manufacturer’s protocol: anti-mIFNγ and anti-mIL-
17 (BD Biosciences), anti-mIL-10 (eBioscience) and anti-
mTNFa (R&Dsystems). The IFN-β level in media supernatant
was determined as previously described (36).
Nanostring Analysis
Total RNA was isolated (Qiazol; Qiagen) and quantitated via
a Nanodrop ND-1000 spectrophotometer (Thermo Scientific).
Next, 50 ng of RNA was hybridized and quantified with a
custom probe set using the NanoString nCounter analysis
system (NanoString Technologies). Gene-expression data were
normalized to housekeeping genes. All values were scaled by a
log2(x – min(x) + 1) function and a heatmap generated using
R-based software.
Western Blot
Cells were lysed in 50 µL of ice-cold Pierce RIPA lysis buffer
(ThermoFisher Scientific) supplemented with 1× complete
protease and phosphatase mixture inhibitor (Sigma). Protein
concentration was measured using a protein DC assay kit.
Whole-cell lysates were denatured for 5min at 85 ◦C in
presence of 1× Sample Buffer and reducing agent (Invitrogen).
Fifty micrograms of samples were separated by SDS/PAGE on
10% gels. Each gel was run initially for 15min at 80V and
then at 120V. Transfer onto nitrocellulose membranes (Bio-
Rad) was done using a Trans-Blot Turbo Transfer system for
10min. Membranes were blocked for 1 h with 5% skim-milk
(Sigma Aldrich) at room temperature in PBS supplemented with
0.05% Tween-20 (PBST). Membranes were probed overnight at
4◦C with the following primary antibodies: anti-cGAS (31659;
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FIGURE 1 | Overexpression of DNAse I ameliorates inflammation in chronic TMPD mediated peritonitis. 8–10 weeks old female C57BL6/J WT mice were either
injected i.p. with 1011 AAV/GFP or AAV/DNAseI particles in 200 uL PBS. 10 weeks later mice were either injected with 500 ul TMPD or un-injected and analyzed from
(Continued)
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FIGURE 1 | two independent experiments 6 months after TMPD injection. All the experiments were performed using the following N’s of mice- AAV/GFP (blue open
bars) AAV/DNAseI (red open bars) are uninjected mice n = 3. AAV/GFP+TMPD (blue closed bars) n = 4 and AAV/DNAseI +TMPD (red closed bars) are injected mice
n = 8. (A) qPCR was performed to measure DNAse1 and GFP gene expression in total tissue, peritoneal lining and kidney. AAV/DNAseI injected mice are indicated in
red bars and AAV/GFP mice are indicated in blue. (B) CD11b+ peritoneal exudate cells stained to identify Ly6Chi monocytes and Ly6Ghi granulocytes. AAV/GFP (blue)
and AAV/DNAse I (red) uninjected mice are indicated by open bars and TMPD injected mice are indicated as closed bars. The top panel shows representative flow
plots and frequency/ numbers are graphed in the bottom panel. (C) CD11b+ splenic cells stained to identify Ly6Chi monocytes. AAV/GFP (blue) and AAV/DNAseI (red)
uninjected mice are indicated by open bars and TMPD injected mice are indicated as closed bars. The right panel shows representative flow plots and
frequency/numbers are graphed in the left panel (D) Sera was collected 6 months after TMPD injection and ANA was measured using HEp2 substrate slides.
Representative image from uninjected mice and AAV/GFP +TMPD injected mice is shown. Representative image is shown for two patterns observed in AAV DNAseI
TMPD injected mice at 20X magnification. (E) Urine samples collected 6 months after TMPD injection were screened for proteinuria using an albumin ELISA assay.
AAV/GFP (blue) and AAV/DNAseI (red) uninjected mice are indicated by open bars and TMPD injected mice are indicated as closed bars. Statistical significance is
represented by *P < 0.05, **P < 0.01.
CST) and anti–beta-actin Peroxidase (A3854; Sigma-Aldrich).
All membranes were washed with PBST and exposed using
the SuperSignal West Pico PLUS chemiluminescent substrate
(ThermoScientific) on ImageQuant LAS4000 mini Imager
(GE Healthcare).
H & E Staining of Tissues
All tissues were fixed in 10% neutral buffered formalin for
24–48 h before being processed and paraffin-embedded. Five-
micrometer-thin sections were stained by H&E in an automated
stainer (Leica Autostainer XL). Histomorphology of each H&E
slides was evaluated by Applied Pathology Systems at low
and high-power field on Olympus BX40 microscope, and the
images were captured with Olympus cellSens Entry software at
indicated magnifications.
Statistical Analysis
All data were analyzed by non-parametric Mann-Whitney test
using GraphPad Prism Software (GraphPad Software, San Diego,
CA). Experiments are reported as mean +/– SEM. Differences
are designated as one asterisk if p < 0.05, as two asterisks if p <
0.01 and three asterisks if p < 0.001.
RESULTS
Overexpression of DNAseI Enzyme
Ameliorates Inflammation in Chronic
TMPD Mediated Peritonitis
TMPD (2,6,10,14-Tetramethylpentadecane) or pristane is a
naturally occurring hydrocarbon oil, which when introduced into
the peritoneal cavity induces features of SLE in non-autoimmune
prone mice (34). These include systemic inflammation,
autoantibody production and glomerulonephritis. TMPD-driven
lupus in B6 mice is highly dependent on TLR7 (30, 31), while
the role of TLR9 is less straightforward. In general, TLR9 is
required for the production of anti-dsDNA autoantibodies
(2), but TLR9−/− SLE-prone mice invariably develop more
severe autoimmunity, and TLR9−/− TMPD-injected BALB/c
mice develop much more severe renal disease than their
TLR9-sufficient littermates (37). Since TMPD induces cell
death, DNA- and RNA-associated-cellular debris is likely to
accumulate in the peritoneal cavity and other tissues throughout
the body (34, 38). In addition, dysregulation of extracellular
enzymes like DNAseI and DNAse1L3 that degrade DNA and
DNA-associated complexes (microparticles) released from
dying cells have also been implicated in SLE (9). DNAse1 is
the most abundant secreted endonuclease, that is primarily
expressed in the salivary glands, kidneys and gut. To explore
the role of extracellular DNA in TMPD-induced lupus, we
overexpressed DNase I using AAV9 that leads to widespread
expression in order to test whether it could limit DNA
uptake and thereby prevent or enhance clinical manifestations
of SLE.
B6 mice were first inoculated with AAV-9 expressing
either GFP or DNaseI, and then injected with TMPD 10
weeks later. 6 months post-TMPD injection, these mice were
evaluated for both DNAseI expression and features of systemic
autoimmunity. The levels of DNAseI were examined in multiple
tissues and found to be expressed at high levels in both
the kidney and peritoneal lining in mice that were injected
with AAV-9 expressing DNaseI as compared to mice that
received AAV-GFP. Similarly, high level of GFP expression
was detected only in mice that received AAV-GFP and
not in AAV-DNAseI injected mice (Figure 1A). TMPD leads
to an inflammatory infiltrate in the peritoneal cavity that
includes both CD11b+ Ly6Chi monocytes and CD11b+ Ly6Ghi
granulocytes. We found that the frequency and total number
of both CD11b+ Ly6Chi inflammatory monocytes and CD11b+
Ly6Ghi granulocytes in the peritoneal exudate was dramatically
decreased in the AAV/DNAseI+TMPD mice compared to
the AAV/GFP+TMPD mice (Figure 1B). We also evaluated
the spleen of these mice and observed reduced frequency
and number of CD11b+ Ly6Chi inflammatory monocytes in
AAVDNaseI treated mice that received TMPD (Figure 1C).
We next evaluated the autoantibody profiles of TMPD treated
mice and observed that the mice expressing AAV DNAseI
showed very different ANA patterns when compared to the
AAV GFP treated mice. Fifty percent of the AAV/GFP+TMPD
sera gave a homogenous nuclear staining pattern, indicative
of autoantibodies reactive with dsDNA, while the sera from
the AAV/DNAseI+TMPD mice gave either a cytoplasmic
and/or a speckled nuclear pattern (Figure 1D). Finally, the
AAV/DNAseI+TMPD mice developed less severe renal disease
as indicated by proteinuria levels (Figure 1E). These results
highlight the importance of DNA sensing in TMPD mediated
systemic autoimmunity.
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FIGURE 2 | STING and cGAS deficiency exacerbate disease in chronic model of TMPD induced autoimmunity. 12–16 week-old female WT, STINGKO or cGASKO
mice were either uninjected (open bars, n = 5) or injected with 500 ul of TMPD (closed bars, n = 15) were analyzed from two independent experiments. (A) 6 months
(Continued)
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FIGURE 2 | later, peritoneal exudate cells were evaluated by flow cytometry. Live and single Ly6C−Ly6G− cells were gated for CD11b+ and F4/80hi. The top panel
indicates representative flow plots from uninjected mice (WT = blue open bar, STINGKO = green open bar and cGASKO = red open bar). The middle panel shows
representative flow plots from injected animals (closed bars) and the graphs for both frequency and numbers of CD11b+ and F4/80hi cells are shown in the bottom
panel. (B) Flow cytometry was performed on splenocytes and double negative T cells (CD4− CD8−) were identified as CD3+ B220+ and CD11b+ and Ly6Chi cells
were identified as inflammatory monocytes. The frequency of double negatives and cell numbers for inflammatory monocytes are graphed. (C) Sera was collected 3
months after TMPD injection and ANAs were detected using HEp2 substrate slides at 1:50 serum dilution. The representative images from each genotype and
condition are shown at 20X magnification in the top panel. The slides were scored for fluorescence intensity and the scores are graphed at the bottom. Anti-ds DNA
antibodies were measured in the serum at 3 months after TMPD injection (closed bars, n = 6). Sera from a WT/Faslpr strain was used as a positive control. (D)
Proteinuria was assessed in urine collected 6 months after TMPD injection by using an albumin ELISA assay. Statistical significance is represented by *P < 0.05.
STING and cGAS Deficiency Exacerbate
Disease in a Chronic Model of TMPD
Induced Autoimmunity
The development of autoimmunity progresses over a 6-month
time course following administration of TMPD. To evaluate the
role of STING and/or cGAS in disease progression, we injected
WT, STINGKO and cGASKO with TMPD and assessed them
6 months later for various features of autoimmune disease.
While B6 mice do not develop kidney pathology, they do
develop immune cell abnormalities and modest proteinurea.
We evaluated several parameters of inflammation, focusing
first on the inflammatory infiltrate in the peritoneal cavity.
We found a comparable frequency and number of CD11b+
Ly6Chi monocytes and CD11b+ Ly6Ghi granulocytes in the
TMPD-injected STING and cGAS deficient animals as in
the TMPD-injected WT mice (Supplementary Figure S1A).
However, within the cells that were CD11b+ Ly6C− Ly6G−
we found a myeloid subset that was CD11b+ and F4/80hi
(Figure 2A). This subset of cells was Tim4+ in uninjected mice
but Tim4− in all TMPD injected mice indicating that these
are not residentmacrophages (Supplementary Figure S1B). This
CD11b+F4/80hi macrophage subset was increased in STING
and cGAS deficient mice as compared to the WT mice both
in frequency and number (Figure 2A). Several studies have
reported distinct macrophage subsets to be pathological and
major contributors of renal disease in both SLE prone patients
and mice (39, 40). We also analyzed different immune cell
subsets in the spleen and found that the numbers of Cd11b+
Ly6Chi monocytes was increased in the spleen of STING and
cGAS deficient pristane injected mice as compared to the WT.
Moreover, we observed an increased percentage of CD3+ B220+
(CD8 CD4 double negative) T cells in the STING and cGAS
deficient pristane injected mice as compared to the WT pristane
injected mice (Figure 2B and Supplementary Figure S1C).
These double negative cells are expanded in SLE patient
populations and contribute to kidney disease (41, 42). Overall,
we found increased frequency and number of cellular subsets that
contribute to disease pathology both in the peritoneal lavage and
in the spleen of the STING and cGAS deficient mice.
To further evaluate TMPD-injected WT, STINGKO and cGAS
KO mice we examined serum for autoantibody production by
immunofluorescent staining of HEp2 cells. Both STING- and
cGAS-deficient mice developed detectable autoantibody levels
by 12 weeks post TMPD injection, while the WT mice did
not, as quantified in the bottom panel (Figure 2C left). We
also quantified the production of anti-ds DNA antibodies in the
serum and observed that the STINGKO and cGASKO TMPD
injected animals had increased anti-dsDNA antibody titers as
compared to WT injected mice (Figure 2C right). We also
measured the status of serum cytokines in these animals and
found increased levels of IL10, IL17, IFNγ and TNFα in
STINGKO and cGASKO TMPD injected animals compared toWT
mice (Supplementary Figure S1D).
Renal function was evaluated by assaying albumin titers in
urine samples and both STINGKO and cGASKO injected mice
showed evidence of increased proteinuria as compared to theWT
injected mice (Figure 2D). Taken together, our data suggests that
STING- or cGAS-deficient mice were not protected from TMPD-
induced SLE, and even exhibited features of autoimmunity that
were severe than their wild type counterparts.
Exacerbation of TMPD-Induced SLE in
cGAS or STING Deficient Mice Is
Dependent on Endosomal TLRs
Our previous study showed that STING deficient macrophages
when stimulated with TLR9 and TLR7 ligands CpGB and CL097,
respectively, produced increased levels of the proinflammatory
cytokines IL6 and TNFα as compared to STING sufficient
cells (29). This hyper-responsiveness correlated with reduced
expression of genes involved in negative regulation of TLR
signaling such as A20, suppressor of cytokine signaling 1
(SOCS1) and 3 (SOCS3) (29). To determine whether the STING-
exacerbated features of SLE were dependent on endosomal
TLRs in vivo, we generated STINGKO Unc93B1KO and cGASKO
Unc93B1KO double deficient lines. We then injected single
Unc93B1KO, the double deficient mice, and their Unc93B1-
sufficient counterparts with TMPD, and evaluated them for
features of systemic autoimmunity 5 months later. As above,
the number of CD11b+ F/480hi macrophages in the peritoneal
cavity was increased in STINGKO and cGASKO mice as compared
to WT mice and significantly reduced in cGASKO UNC93B1KO
and STINGKO Unc93B1KO double-deficient mice (Figure 3A).
We also found that again both STINGKO and cGASKO mice
developed higher levels of autoantibody than the WT mice, but
failed to produce autoantibodies if they were Unc93B1-deficient
(Figure 3B). Moreover, the proteinuria levels of STING and
cGAS deficient mice were significantly higher than the WTmice,
but STING/Unc93B1 and cGAS/Unc93B1double deficient mice
failed to develop detectable proteinuria (Figure 3C). Collectively,
these findings indicate that the elevated features of autoimmunity
observed in cGAS or STING-deficient mice was abrogated when
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FIGURE 3 | Exacerbation of TMPD-induced SLE in cGAS or STING deficient mice is dependent on endosomal TLRs. 12–16 week old female WT (blue), STINGKO
(red), cGASKO (green), UNCKO (blue with dots), UNCKO STINGKO (red with dots), and UNCKOcGASKO (green with dots) mice were injected with 500 ul of TMPD
(Continued)
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FIGURE 3 | (n = 10). Uninjected controls are indicated as open bars (n = 4 per genotype). The mice were analyzed 5 months post injection from two independent
experiments. (A) Peritoneal exudate cells were evaluated by flow cytometry. Live and single Ly6C−Ly6G− cells were gated for CD11b+ and F4/80hi. Representative
flow plots for WT STINGKO, cGASKO injected mice are shown in the top panel, the double deficient injected mice in the middle panel and the graphs for cell frequency
and cell numbers are shown in bottom panel. (B) Sera was collected 3 months after TMPD injection and ANA were detected using HEp2 substrate slides at 1:50
serum dilution. The representative images from each genotype and condition are shown at 20X magnification in the top and middle panels and the scores for
fluorescence intensity are graphed in the bottom. (C) Proteinuria was assessed in urine collected 5 months after TMPD injection by using an albumin ELISA assay.
Statistical significance is represented by *P < 0.05.
endosomal TLR signaling was abolished by deletion of Unc93B1
in vivo.
cGAS Deficiency Does Not Rescue
SLE-Prone MRL/Faslpr Mice
We had previously reported exacerbation of autoimmune
features in STING-deficient Faslpr mice generated by
intercrossing B6/129 STING-deficient mice with MRL/Faslpr
mice (29). To avoid any risk alleles that could be linked to
the cGAS locus and modify disease outcome, we directly
generated cGAS deficient MRL/Faslpr mice using a CRISPR/Cas9
genome editing strategy in MRL/lpr mice. We confirmed
cGAS deficiency in the gene-edited strain by stimulating
cGAS-deficient and control bone marrow derived macrophages
(BMDMs) with ISD and measuring interferon production.
cGASKO/ Fas lpr cells failed to produce Interferonβ (IFNβ)
compared to WT/Faslpr cells in response to ISD, confirming that
the CRISPR generated strain was functionally cGAS deficient
(Figure 4A left). We also immunoblotted lysates obtained from
WT/Faslpr and cGASKO/Fas lpr BMDMs. As expected, we found
no detectable levels of cGAS protein in macrophages from
cGASKO/Fas lpr mice whereas WT/Faslpr macrophages expressed
cGAS protein (Figure 4A right). cGASKO/Faslpr and WT/Faslpr
littermate controls were then evaluated for various SLE features
and WT and cGAS deficient mice on a C57BL/6 background
were used as negative controls since they do not develop
autoimmunity spontaneously. Survival of the cGASKO/Faslpr
mice was slightly compromised as compared to their WT/Faslpr
littermates (Figure 4B). The cGASKO/Faslpr mice developed
significantly higher levels anti-nucleosome antibodies in the
serum as compared toWT/Faslpr littermate controls (Figure 4C).
The cGASKO/Faslpr mice show increased proteinuria in the urine
and increased cellular infiltrate in the kidneys as compared
to the WT/Faslpr littermate controls (Figure 4D). However,
splenomegaly or lymphadenopathy showed only trending
increases in cGASKO/Faslpr as compared to littermate controls
(Figure 4E). Similarly, the percentage of CD3+ B220+ (CD8
CD4 double negative) T cells or pDC were only modestly
increased in the cGASKO/Faslpr mice compared to WT/Faslpr
(Figure 4F). In addition, we also performed gene expression
analysis in the total splenocytes obtained from these mice and we
did not see any significant diffrences between the cGASKO/Faslpr
mice compared to WT/Faslpr (Supplementary Figure S2A).
Importantly, our data indicates that neither STING nor cGAS
deficiency rescue MRL/lpr mice from SLE and are therefore
unlikely to sense the extracellular DNA that accumulates in this
model. Thus, the importance of the cGAS/STING pathway in the
promotion of autoinflammation does not necessarily translate to
the promotion of SLE.
DISCUSSION
Engagement of cGAS and the endosomal DNA sensor TLR9,
can lead to the production of type I IFNs and proinflammatory
cytokines. Stressed, damaged, or dying cells can provide sources
of endogenous ligands that can activate both pathways. The
importance of TLRs in SLE disease pathogenesis has been
demonstrated by both loss-of-function and gain-of-function
mutations in multiple animal models of SLE (3, 43–45), whereas
DNA sensing mediated by the cGAS-STING pathway has been
implicated in several human monogenic autoinflammatory
diseases (46–48), as well as in mouse models of type I
interferonopathies (49–51). In contrast to autoinflammatory
diseases, where STING activation amplifies inflammation, our
initial study showed that the STING pathway can attenuate
clinical manifestations of SLE (29). We have now extended our
initial observation to a chronic inducible model of SLE (TMPD
induced SLE) as well as gene-targeted MRL/lpr SLE-prone
mice, where we can monitor the progression of the disease
without the caveat of additional risk alleles due to mixed genetic
backgrounds. Our findings show that STING or cGAS deficiency
does not cure lupus in either case. Rather, consistent with our
earlier work (29), STING or cGAS deficiency leads to an earlier
onset of SLE as measured by autoantibody levels in the serum
and proteinuria in the urine. These data provide a cautionary
note for the use of cGAS-STING targeted therapies for the
treatment of SLE.
We have now also shown that neither Unc93B1/STING
nor Unc93B1/cGAS mice develop TMPD induced SLE. These
data further demonstrate that even in mice that fail to express
STING, SLE is still dependent on endosomal TLRs. To determine
whether DNA plays a role as an instigator of TMPD-induced
lupus, we generated mice with increased levels of extracellular
DNAse I using a one-time i.p. injection of AAV encoding DNAse
I. We initially set out to test the premise that the protective role
of STING (and TLR9) was DNA-dependent, and if this were
the case, depletion of DNA should have resulted in an amplified
TLR7 signal and led to a more severe clinical outcome. Instead,
DNAseI-AAV-treated mice did not make autoantibodies against
dsDNA, as indicated by the ANA staining pattern, and did
not even develop other clinical manifestations of SLE. These
data point to a critical role for a DNA sensor, possibly TLR9,
in promoting the development of TMPD-induced SLE, and
suggest that there may be a bimodal interplay between TLR7
and TLR9 in disease initiation and then disease progression.
Alternatively, a DNA sensor other than cGAS or TLR9 may be
involved. DNAseI-treated mice injected with TMPD show an
overall reduction in inflammation and proteinuria but a very
different autoantibody profile which could be more RNA driven,
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FIGURE 4 | cGAS deficiency does not rescue SLE-prone MRL/Faslpr mice.
(A) BMDMs were isolated from WT/ Faslpr and cGAS KO/ Faslpr mice. These
(Continued)
FIGURE 4 | cells were either transfected or un-transfected with ISD 5 uM and
interferon β ELISA was performed after overnight treatments. (B) BMDM cell
lysates were prepared and western blot was performed to detect cGAS levels.
Actin was blotted as loading control. (B) WT/Faslpr (n = 10) and
cGASKO/Faslpr (n = 18) mice were observed until the time of death and Kaplan
Meier survival analysis was performed. (C) Anti-nucleosome ELISA was
performed for 12–16 week old mice B6 WT and B6 cGASKO mice (open bars),
WT/Faslpr littermates (blue bar, n = 16), cGASKO/Faslpr mice (green bar, n =
16). (D) Urine samples from 16 week old B6 WT and B6 cGASKO mice (open
bars), WT/Faslpr littermates (blue bar, n = 16), cGASKO/Faslpr mice (green bar,
n = 18) were screened for proteinuria using an albumin ELISA assay. H&E
staining was performed to analyze cellular infiltrate WT/Faslpr littermates (blue
bar, n = 7), cGASKO/Faslpr mice (green bar, n = 7). (E) Spleen and lymph
nodes weights were determined at 12 weeks of age (n = 16 mice each for
WT/Faslpr and cGASKO/Faslpr). (F) Flow cytometry was performed on
splenocytes and double negative T cells (CD4− CD8−) were identified as
CD3+ B220+. To enumerate pDCs, B220− CD3− CD11c+ splenocytes were
gated for SiglecH+ and Bst2+ cells. Representative flow plot is shown for each
cell type and corresponding genotype in the top/middle panels and the
frequency of cells is graphed in the bottom. All the flow analysis was
performed on 12 week old female mice, (n = 16 mice each for WT/Faslpr and
cGASKO/Faslpr). Statistical significance is represented by *P < 0.05.
a phenomenon similar to the impact of TLR9-deficiency. TLR9-
and TLR7-deficient SLE prone mice fail to make autoantibodies
reactive with DNA and RNA, respectively, while TLR7-deficient
and TLR7/TLR9 double deficient mice develop much less severe
clinical phenotypes and exhibit markedly prolonged survival (2).
It is also important to mention, that although DNAse1 is the
most abundant secreted endonuclease expressed in some tissues
including the kidneys, the AAV gene delivery approach here
could have led to a more widespread expression of DNAseI than
that seen under physiological conditions.
Although the mechanisms remain unresolved, this study
reinforces the importance of investigating both proinflammatory
and anti-inflammatory activities of nucleic acid-sensors. Both the
TLR9 and STING pathways promote the IFN- and NFκB-driven
expression of proinflammatory cytokines and chemokines, but
at the same time induce negative regulators of these pathways.
Thus, the outcome of nucleic acid sensor engagement will
depend on the balance between positive and negative regulators
of inflammation and transcriptional regulation of the relevant
genes which is likely to reflect activation status of the receptor
expressing cells. The dual functionality for cytosolic pathways
is not surprising since a published study showed that the
cytosolic RNA sensor, RIG-I also dampens TLR responses in
myeloid cells by suppressing TLR driven interleukin 12 (IL-12b)
gene transcription (52). The evidence of increased autoantibody
production due to STING deficiency is also seen in a DNAse1L3-
deficient mouse model used to evaluate SLE, where DNAse1L3
another extracellular DNAse clears microvesicle-associated
DNA. The DNAse1L3 knockout mice were crossed with STING-
deficient mice and serum titers of anti-dsDNA IgG as determined
by ELISA, were higher in DNAse1L3/ STING double knockout
mice than in single DNAse1L3 knockout mice (7).
More recently, several groups have described a role for
the STING pathway in the clearance of DNA by autophagy
(53, 54), suggesting that STING deficiency could lead to reduced
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clearance of DNA. The ensuing accumulation of DNA in
endosomal compartments of these cells could then enhance
TLR dependent cytokine production through a cell intrinsic
mechanism. DNAse II-deficient mice provide another example
of excessive DNA accrual leading to the activation of multiple
nucleic acid sensing pathways since the cGAS-STING, AIM2,
and endosomal TLRs all have been shown to contribute to the
development of autoimmunity or autoinflammation in this
model (16, 55, 56). It is also possible that different DNA sensors
may function in tissue specific manner for instance cGAS STING
pathway can still contribute to certain aspects of disease such as
the cutaneous lupus features as suggested by Skopelja-Gardner
et al. (20). A better understanding of the interplay between cells
responding to endogenous nucleic acid ligands will provide
important insights for preventing the onset and progression of
both autoinflammatory and autoimmune diseases in patients
suffering from these conditions.
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